Regarding pooled adverse events, deaths occurred in 5.1% of patients (GH group) and 7.3% of patients (placebo group), worsening HF in 9% of patients (GH group) and 17.4% of patients (placebo group). This evidence concerns the gene GH1 and hydrops fetalis.